A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 14610140.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.
Medical subject headings
- Guillain-Barre Syndrome
- Interferon-beta
- Recombinant Proteins